Entrada Therapeutics vs Xenetic Biosciences
TRDA and XBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How TRDA and XBIO compare
Entrada Therapeutics is the larger company, worth 48 times as much as Xenetic Biosciences ($212M against $4.4M).
Xenetic Biosciences grew revenue faster over the last twelve months (33.3% versus −93.5% for Entrada Therapeutics).
Xenetic Biosciences keeps more of each dollar of sales as profit, with a net margin of −75.9% compared with −4058% at Entrada Therapeutics.
Xenetic Biosciences scores higher on the StockData Score (12 against 6 for Entrada Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | TRDA | XBIO |
|---|---|---|
| Size and price | ||
| Market cap | $212M | $4.4M |
| Share price | $5.44 | $1.87 |
| Change, 1 year | −25.1% | −29.6% |
| Change, 5 years | −83.4% | −87.4% |
| Beta (5Y) | 0.97 | 0.89 |
| Employees | 152 | 2 |
| StockData Score | ||
| Total score | 6 | 12 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 53.3× | 1.3× (better) |
| P/B | 1.1× | 0.7× (better) |
| FCF yield | −64.4% | – |
| Fair value | – | $4.53 |
| Margin of safety | – | 58.8% |
| Growth | ||
| Revenue growth (TTM) | −93.5% | 33.3% (better) |
| Revenue growth, 5Y average | – | 46.8% |
| Profitability | ||
| Operating margin | −4304% | −81.0% (better) |
| Net margin | −4058% | −75.9% (better) |
| FCF margin | −3428% | – |
| Return on equity | −59.9% | −47.0% (better) |
| Return on invested capital | −1406% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 7.85 (better) | 7.43 |
| Altman Z-score | −1.53 (better) | −37.30 |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 75.6% | 6.5% |
| Held by insiders | 14.8% | 12.2% |
| Insider net buying, 12 months | −$11.5M | – |
| Short interest, % of float | 8.5% | 1.8% |
Go deeper
- TRDA stock overview
- TRDA income statement
- TRDA valuation and score
- XBIO stock overview
- XBIO income statement
- XBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.